CY1117766T1 - Αντιβακτηριδιακα παραγωγα κινολινης - Google Patents
Αντιβακτηριδιακα παραγωγα κινολινηςInfo
- Publication number
- CY1117766T1 CY1117766T1 CY20161100496T CY161100496T CY1117766T1 CY 1117766 T1 CY1117766 T1 CY 1117766T1 CY 20161100496 T CY20161100496 T CY 20161100496T CY 161100496 T CY161100496 T CY 161100496T CY 1117766 T1 CY1117766 T1 CY 1117766T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compounds
- preparation
- pharmaceutically acceptable
- treatment
- kinolin
- Prior art date
Links
- 230000000844 anti-bacterial effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000035143 Bacterial infection Diseases 0.000 abstract 2
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 2
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 150000002500 ions Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται σε νέα παράγωγα υποκατεστημένης κινολίνης, σύμφωνα με τον γενικό τύπο (la) ή τον τύπο (lb): συμπεριλαμβανομένων οποιωνδήποτε στερεοχημικώς ισομερών μορφών αυτών, ενός N-οξειδίου αυτών, ενός φαρμακευτικά αποδεκτού άλατος αυτών, ή ενός επιδιαλυτωμένου άλατος αυτών. Οι αξιούμενες ενώσεις είναι χρήσιμες για την θεραπεία μίας βακτηριδιακής μόλυνσης. Επίσης αξιώνεται μία σύνθεση που περιλαμβάνει έναν φαρμακευτικά αποδεκτό φορέα και, ως ενεργό συστατικό, μία θεραπευτικά αποτελεσματική ποσότητα των αξιουμένων ενώσεων, η χρήση των αξιουμένων ενώσεων ή των σύνθετων ιόντων για την παρασκευή ενός φαρμακευτικού μέσου για την θεραπεία μίας βακτηριδιακής μόλυνσης και μία διεργασία για την παρασκευή των αξιουμένων ενώσεων.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06125499 | 2006-12-06 | ||
| EP07847811.2A EP2099758B1 (en) | 2006-12-06 | 2007-12-04 | Antibacterial quinoline derivatives |
| PCT/EP2007/063313 WO2008068267A1 (en) | 2006-12-06 | 2007-12-04 | Antibacterial quinoline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1117766T1 true CY1117766T1 (el) | 2017-05-17 |
Family
ID=38126091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20161100496T CY1117766T1 (el) | 2006-12-06 | 2016-06-08 | Αντιβακτηριδιακα παραγωγα κινολινης |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US8415475B2 (el) |
| EP (1) | EP2099758B1 (el) |
| JP (1) | JP5466011B2 (el) |
| KR (1) | KR101490222B1 (el) |
| CN (2) | CN101553470A (el) |
| AP (1) | AP2479A (el) |
| AR (1) | AR064151A1 (el) |
| AU (1) | AU2007328887B2 (el) |
| BR (1) | BRPI0720220B8 (el) |
| CA (1) | CA2669819C (el) |
| CL (1) | CL2007003514A1 (el) |
| CY (1) | CY1117766T1 (el) |
| DK (1) | DK2099758T3 (el) |
| EA (1) | EA016733B1 (el) |
| ES (1) | ES2573689T3 (el) |
| HK (1) | HK1208437A1 (el) |
| HR (1) | HRP20160585T1 (el) |
| HU (1) | HUE028769T2 (el) |
| IL (1) | IL199083A (el) |
| JO (1) | JO3271B1 (el) |
| ME (1) | ME02498B (el) |
| MX (1) | MX2009005978A (el) |
| MY (1) | MY181645A (el) |
| NO (1) | NO341983B1 (el) |
| NZ (1) | NZ576823A (el) |
| PL (1) | PL2099758T3 (el) |
| PT (1) | PT2099758E (el) |
| RS (1) | RS54794B1 (el) |
| SI (1) | SI2099758T1 (el) |
| TW (1) | TWI406659B (el) |
| UA (1) | UA100972C2 (el) |
| WO (1) | WO2008068267A1 (el) |
| ZA (1) | ZA200903950B (el) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2841426T3 (pl) | 2012-04-27 | 2017-03-31 | Janssen Pharmaceutica N.V. | Przeciwbakteryjne pochodne chinoliny |
| WO2013160435A1 (en) | 2012-04-27 | 2013-10-31 | Janssen Pharmaceutica Nv | Antibacterial quinoline derivatives |
| ES2619610T3 (es) | 2012-10-16 | 2017-06-26 | Janssen Pharmaceutica Nv | Moduladores de ROR-gamma-t de quinolinilo enlazado con heteroarilo |
| JP6251277B2 (ja) | 2012-10-16 | 2017-12-20 | ヤンセン ファーマシューティカ エヌ．ベー． | ＲＯＲ−ガンマ−ｔのフェニル結合キノリニルモジュレーター |
| SMT201700347T1 (it) | 2012-10-16 | 2017-09-07 | Janssen Pharmaceutica Nv | Modulatori di ror-gamma-t chinolinilici legati a metilene |
| CN105873439A (zh) | 2013-10-15 | 2016-08-17 | 詹森药业有限公司 | RORγt的烷基连接的喹啉基调节剂 |
| US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
| US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
| US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
| US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
| WO2015057626A1 (en) | 2013-10-15 | 2015-04-23 | Janssen Pharmaceutica Nv | QUINOLINYL MODULATORS OF RORyT |
| US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
| CN105330595B (zh) * | 2014-07-14 | 2019-12-10 | 上海嘉坦医药科技有限公司 | 吡啶衍生物及其作为抗分支杆菌的应用 |
| CA2954872C (en) * | 2014-07-14 | 2019-08-13 | Cisen Pharmaceutical Co., Ltd. | Pyridine derivatives and anti-mycobacterial use thereof |
| US20180000810A1 (en) * | 2015-01-27 | 2018-01-04 | Janssen Pharmaceutica Nv | Dispersible compositions |
| CN108473428B (zh) * | 2016-01-13 | 2021-07-23 | 上海嘉坦医药科技有限公司 | 一种吡啶衍生物类化合物的制备方法及其中间体和晶型 |
| CN105601566A (zh) * | 2016-02-02 | 2016-05-25 | 张敏 | 一种护理烧伤后感染的药物组合物 |
| EP3426255B1 (en) * | 2016-03-07 | 2022-11-30 | The Global Alliance for TB Drug Development, Inc. | Antibacterial compounds and uses thereof |
| WO2018048882A1 (en) | 2016-09-06 | 2018-03-15 | The Research Foundation For The State University Of New York | Positron imaging tomography imaging agent composition and method for bacterial infection |
| WO2019145919A1 (en) * | 2018-01-29 | 2019-08-01 | Cadila Healthcare Limited | Heterocyclic compounds useful as antibacterial agents |
| MX2023004635A (es) * | 2020-10-22 | 2023-05-12 | Lunella Biotech Inc | Los inhibidores de atp mitocondrial que fijan como objetivo la subunidad gamma previenen la metastasis. |
| WO2023178035A1 (en) | 2022-03-14 | 2023-09-21 | Slap Pharmaceuticals Llc | Multicyclic compounds |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998018326A1 (en) * | 1996-10-28 | 1998-05-07 | Department Of The Army, U.S. Government | Compounds, compositions and methods for treating antibiotic-resistant infections |
| PT1527050E (pt) * | 2002-07-25 | 2010-06-22 | Janssen Pharmaceutica Nv | Derivados de quinolina e sua utilização como inibidores de micobactérias |
| ES2333730T3 (es) | 2004-01-23 | 2010-02-26 | Janssen Pharmaceutica Nv | Derivados de quinolina y uso de los mismos como inhibidores de micobacterias. |
| DE602005006101T2 (de) | 2004-01-23 | 2009-07-02 | Janssen Pharmaceutica N.V. | Substituierte chinoline und deren verwendung als inhibitoren von mycobakterien |
| JP4919810B2 (ja) * | 2004-01-29 | 2012-04-18 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | マイコバクテリア抑制剤としての使用のためのキノリン誘導体 |
| JO2524B1 (en) | 2004-05-28 | 2010-03-17 | جانسن فارمسيتكا ان في | Use of substituted quinoline derivatives to treat drug-resistant microbial diseases |
| WO2006035051A1 (en) | 2004-09-28 | 2006-04-06 | Janssen Pharmaceutica N.V. | A bacterial atp synthase binding domain |
| EE05394B1 (et) * | 2004-12-24 | 2011-04-15 | Janssen Pharmaceutica N.V. | Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis |
| CA2528849C (en) * | 2005-06-08 | 2014-01-14 | Janssen Pharmaceutica N.V. | Quinoline derivatives as antibacterial agents |
| JO2952B1 (en) * | 2005-08-03 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Quinoline derivatives acting as antibacterial agents |
| JO2855B1 (en) * | 2005-08-03 | 2015-03-15 | شركة جانسين فارماسوتيكا ان. في | Quinoline derivatives acting as antibacterial agents |
| JO2837B1 (en) * | 2005-08-03 | 2014-09-15 | جانسن فارمسيتكا ان في | Quinoline derivatives acting as antibacterial agents |
-
2007
- 2007-11-29 JO JOP/2007/0504A patent/JO3271B1/ar active
- 2007-12-04 PL PL07847811T patent/PL2099758T3/pl unknown
- 2007-12-04 AP AP2009004874A patent/AP2479A/xx active
- 2007-12-04 NZ NZ576823A patent/NZ576823A/en not_active IP Right Cessation
- 2007-12-04 MX MX2009005978A patent/MX2009005978A/es active IP Right Grant
- 2007-12-04 HU HUE07847811A patent/HUE028769T2/en unknown
- 2007-12-04 WO PCT/EP2007/063313 patent/WO2008068267A1/en active Application Filing
- 2007-12-04 PT PT07847811T patent/PT2099758E/pt unknown
- 2007-12-04 ES ES07847811.2T patent/ES2573689T3/es active Active
- 2007-12-04 EP EP07847811.2A patent/EP2099758B1/en active Active
- 2007-12-04 JP JP2009539738A patent/JP5466011B2/ja not_active Expired - Fee Related
- 2007-12-04 RS RS20160374A patent/RS54794B1/sr unknown
- 2007-12-04 DK DK07847811.2T patent/DK2099758T3/en active
- 2007-12-04 EA EA200970535A patent/EA016733B1/ru unknown
- 2007-12-04 KR KR1020097012967A patent/KR101490222B1/ko not_active Expired - Fee Related
- 2007-12-04 CN CNA2007800449358A patent/CN101553470A/zh active Pending
- 2007-12-04 CN CN201510088659.1A patent/CN104744361B/zh not_active Expired - Fee Related
- 2007-12-04 US US12/516,065 patent/US8415475B2/en active Active
- 2007-12-04 UA UAA200904716A patent/UA100972C2/ru unknown
- 2007-12-04 SI SI200731779A patent/SI2099758T1/sl unknown
- 2007-12-04 CA CA2669819A patent/CA2669819C/en active Active
- 2007-12-04 ME MEP-2016-109A patent/ME02498B/me unknown
- 2007-12-04 MY MYPI20092283A patent/MY181645A/en unknown
- 2007-12-04 AU AU2007328887A patent/AU2007328887B2/en not_active Ceased
- 2007-12-04 BR BRPI0720220A patent/BRPI0720220B8/pt not_active IP Right Cessation
- 2007-12-05 AR ARP070105444A patent/AR064151A1/es unknown
- 2007-12-05 CL CL200703514A patent/CL2007003514A1/es unknown
- 2007-12-05 TW TW096146217A patent/TWI406659B/zh not_active IP Right Cessation
-
2009
- 2009-06-02 IL IL199083A patent/IL199083A/en active IP Right Grant
- 2009-06-05 ZA ZA200903950A patent/ZA200903950B/xx unknown
- 2009-07-06 NO NO20092542A patent/NO341983B1/no unknown
-
2015
- 2015-09-10 HK HK15108797.1A patent/HK1208437A1/xx unknown
-
2016
- 2016-05-31 HR HRP20160585TT patent/HRP20160585T1/hr unknown
- 2016-06-08 CY CY20161100496T patent/CY1117766T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1117766T1 (el) | Αντιβακτηριδιακα παραγωγα κινολινης | |
| CY1111188T1 (el) | Αντιβακτηριακα παραγωγα κινολινης | |
| CY1112230T1 (el) | Αντιβακτηριακα παραγωγα κινολινης | |
| CY1117247T1 (el) | Αντιβακτηριακα παραγωγα κινολινης | |
| EA201491982A1 (ru) | Антибактериальные хинолиновые производные | |
| CY1114384T1 (el) | Αντιβακτηριακα παραγωγα κινολινης | |
| CY1110706T1 (el) | Αντιβακτηριδιακα παραγωγα κινολινης | |
| CY1118515T1 (el) | Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες | |
| CY1112027T1 (el) | Αντιβακτηριακα παραγωγα κινολινης | |
| EA201491971A1 (ru) | Антибактериальные хинолиновые производные |